rethinkTHC Search
Menu
Study breakdown

Overview of the Enzymes That Build and Break Down the Body's Natural Cannabinoids

ReviewModerate evidence
The takeaway

A comprehensive review of endocannabinoid metabolism identified multiple synthesis and degradation pathways for anandamide and 2-AG, with their metabolic enzymes emerging as drug targets for treating addiction and other conditions.

Read this if you want to understand the molecular machinery that controls the body's natural cannabinoid system.

Multiple synthesis and degradation pathways identified for each endocannabinoid, all potential drug targets

What the researchers found

This review provided an integrative overview of the enzymes controlling endocannabinoid levels. Anandamide (AEA) biosynthesis involves multiple pathways including NAPE-PLD, secretory PLA2, and PLC. The endocannabinoid 2-AG is produced through phosphatidic acid phosphohydrolase, diacylglycerol lipase (DAGL), PI-PLC, and lyso-PLC.

Cellular uptake of endocannabinoids involves a putative membrane transporter or facilitated diffusion. Degradation is handled by FAAH (for anandamide) and both FAAH and MAGL (for 2-AG).

The review discussed therapeutic interventions targeting these metabolic enzymes, including applications for addiction treatment. By modulating the enzymes rather than the receptors, researchers could fine-tune endocannabinoid levels with potentially greater selectivity than directly activating or blocking cannabinoid receptors.

Why it matters

Understanding the full metabolic machinery of the endocannabinoid system is essential for developing targeted drugs. Each enzyme in the pathway represents a potential drug target that could raise or lower endocannabinoid levels in specific ways, offering more precision than administering cannabinoids directly.

The numbers in context

AEA synthesis: NAPE-PLD, PLA2, PLC pathways. 2-AG synthesis: DAGL, PI-PLC, lyso-PLC, phosphatidic acid phosphohydrolase. Degradation: FAAH (AEA), MAGL and FAAH (2-AG). Transport: putative membrane transporter.

How the study worked

Integrative review of published research on endocannabinoid biosynthesis, transport, and degradation enzymes. Covered enzyme characterization, metabolic pathways, and potential therapeutic applications.

What this study cannot tell us

Rapidly evolving field where new enzymes and pathways were still being discovered. Some proposed pathways were based on limited evidence. The putative membrane transporter remained controversial. Therapeutic applications were largely preclinical.

How to read the evidence

Integrative review of molecular biology research. Provides comprehensive enzyme characterization but therapeutic applications were largely preclinical.

When this study was published

Published in 2007. Understanding of endocannabinoid metabolism has continued to expand, with new enzymes and pathways identified since this review.

The bigger picture

The complexity of endocannabinoid metabolism, with multiple redundant pathways for both synthesis and degradation, explains why the system is so tightly regulated and why targeting individual enzymes can produce specific effects without completely disrupting the system.

Questions still open

  • Which metabolic enzyme targets will prove most therapeutically useful? Can enzyme-targeted drugs achieve sufficient tissue selectivity to avoid systemic side effects?

Common questions

How does the body control its own cannabinoid levels?
The body produces endocannabinoids (anandamide and 2-AG) on demand through specific enzymes and breaks them down quickly through other enzymes (FAAH and MAGL). This tight control allows precise regulation of cannabinoid signaling in different tissues.
Could targeting these enzymes lead to new medicines?
Yes. By inhibiting the enzymes that break down endocannabinoids (like FAAH or MAGL), researchers can boost the body's natural cannabinoid signaling. This approach is being explored for treating addiction, pain, anxiety, and other conditions.

Read the original research

Critical enzymes involved in endocannabinoid metabolism.

Protein and peptide letters, 14(3), 237-46

Citation

Basavarajappa, Balapal S. (2007). Critical enzymes involved in endocannabinoid metabolism.. Protein and peptide letters, 14(3), 237-46.

Explore the wider topic